^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)

    i
    Other names: MAPK8IP2, Mitogen-Activated Protein Kinase 8 Interacting Protein 2, JIP2, IB2, JNK-Interacting Protein 2, PRKM8IPL, C-Jun-Amino-Terminal Kinase-Interacting Protein 2, JNK MAP Kinase Scaffold Protein 2, Islet-Brain 2, IB-2, Mitogen-Activated Protein Kinase 8-Interacting Protein 2, JNK MAP Kinase Scaffold Protein JIP2, PRKM8 Interacting Protein-Like, Homologous To Mouse JIP-1, Islet-Brain-2, JIP-2
    Associations

    News

    Trials
    2ms
    Identification of a signature gene set for oxaliplatin sensitivity prediction in colorectal cancer. (PubMed, Front Oncol)
    Our study identifies a novel four-gene signature that is strongly associated with oxaliplatin sensitivity in colorectal cancer. These findings support developing prognostic biomarkers to optimize oxaliplatin use, aiming to identify sensitive patients and avoid treatment for those with resistance.
    Journal
    |
    MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)
    |
    oxaliplatin
    1year
    Ginsenoside Rh2 promotes cell apoptosis in T-cell acute lymphocytic leukaemia by MAPK and PI3K/AKT signalling pathways. (PubMed, Nat Prod Res)
    Moreover, the protein expression ratios of p-PI3K/PI3K and p-AKT/AKT were significantly reduced, and the expression ratios of p-ASK1/ASK1, p-JNK/JNK and p-c-JUN/c-JUN, Bax/Bcl-2, and the levels of cleaved caspase 8, 9, 3 were increased significantly in GRh2-treated Jurkat cells. The results imply that GRh2 induced T-ALL apoptosis by activating the MAPK pathway and inhibiting the PI3K-AKT pathway.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8) • CASP9 (Caspase 9) • MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)
    over1year
    Transcriptome Profiling Associated with CARD11 Overexpression in Colorectal Cancer Implicates a Potential Role for Tumor Immune Microenvironment and Cancer Pathways Modulation via NF-κB. (PubMed, Int J Mol Sci)
    In patient samples, adenoma patients exhibited increased expression of genes associated with the tumor immune microenvironment, such as IL6ST, collagen family members, and CRC transition markers, such as GLI3 and PIEZO2, in CARD11+ adenoma patients. Carcinoma patients showed a dramatic increase in the expression of MAPK8IP2 in CARD11+ carcinoma patients alongside other cancer-related genes, including EMB, EPHB6, and CPEB4.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • CARD11 (Caspase Recruitment Domain Family Member 11) • SPP1 (Secreted Phosphoprotein 1) • EP300 (E1A binding protein p300) • MALT1 (MALT1 Paracaspase) • CCL2 (Chemokine (C-C motif) ligand 2) • GLI3 (GLI Family Zinc Finger 3) • KDM5A (Lysine Demethylase 5A) • CCL22 (C-C Motif Chemokine Ligand 22) • IL1RN (Interleukin 1 receptor antagonist) • IL6ST (Interleukin 6 Signal Transducer) • CXCL1 (Chemokine (C-X-C motif) ligand 1) • CXCL3 (C-X-C Motif Chemokine Ligand 3) • DUSP1 (Dual Specificity Phosphatase 1) • MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)
    |
    HIF1A expression
    2years
    A novel circular RNA, circMAML3, promotes tumor progression of prostate cancer by regulating miR-665/MAPK8IP2 axis. (PubMed, Cell Death Discov)
    The circMAML3 circular characterization was performed using Sanger sequencing, agarose gel electrophoresis assay, RNase R assay and actinomycin D assay...circMAML3 and MAPK8IP2 are upregulated in prostate cancer expression and play an oncogenic role, whereas miR-665 is downregulated in prostate cancer and plays an oncogenic role. Therefore, CircMAML3 may be a potential biomarker for prostate cancer diagnosis, treatment and prognosis.
    Journal
    |
    MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)
    |
    dactinomycin
    over3years
    MAPK8IP2 is a potential prognostic biomarker and promote tumor progression in prostate cancer. (PubMed, BMC Cancer)
    MAPK8IP2 is a potential target for PCa treatment and can serve as a novel biomarker for PCa diagnosis and prognosis evaluation.
    Journal
    |
    TP53 (Tumor protein P53) • CDK12 (Cyclin dependent kinase 12) • MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)
    |
    TP53 mutation
    over3years
    Scaffold protein MAPK8IP2 expression is a robust prognostic factor in prostate cancer associated with AR signaling activity. (PubMed, Asian J Androl)
    These results indicate that MAPK8IP2 is a robust prognostic factor and therapeutic biomarker for prostate cancer. The potential role of MAPK8IP2 in the castration-resistant progression is under further investigation.
    Journal
    |
    MAPK8 (Mitogen-activated protein kinase 8) • MAPK8IP2 (Mitogen-Activated Protein Kinase 8 Interacting Protein 2)
    |
    AR positive • AR expression